Login
Israel-Hamas Conflict
Airstrike
Military
Benjamin Netanyahu
Parade
World Cup
Donald Trump
War
Social Media
Cricket
Wrestling
South America
Artificial Intelligence
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age

Summary by contemporarypediatrics.com
Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
contemporarypediatrics.comcontemporarypediatrics.com

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contemporarypediatrics.com broke the news in on Thursday, June 12, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
SearchBlindspotLocal